The supplier has delivered an extractables report, every component is listed as suitable for bioprocessing, and procurement wants approval. The unresolved question is whether chemicals from the actual assembly can reach the patient, affect the product or disturb the process under the intended conditions. A complete report for one component does not answer that question for a manufacturing train.
Extractables and leachables assessment connects materials, analytical chemistry, process knowledge and toxicology. This article sets out a practical assessment sequence for single-use manufacturing components. It does not prescribe universal extraction conditions, analytical thresholds or patient-exposure limits. Those decisions require the applicable framework, a defined use case and scientifically justified assumptions.
Keep four different questions separate
Extractables are compounds that can be released from a material under defined laboratory extraction conditions. Leachables are compounds that migrate under actual use or relevant simulated-use conditions. An extractables study helps characterize potential chemical contributors; a leachables assessment evaluates their relevance to the manufacturing process and final product.
Material compatibility is a separate question. A tube may resist swelling and retain mechanical strength while releasing a chemical of interest. Conversely, acceptable chemical migration does not demonstrate resistance to pressure, fatigue or adsorption of product. Biological reactivity tests and a material classification also do not replace a process-specific chemical assessment.
Distinguish the supplier dataset from the manufacturer's decision. The supplier can characterize a film, connector or complete assembly under documented conditions. The user must establish whether that evidence covers the installed configuration, fluid composition, contact duration, process position and cumulative exposure. Supplier extractables data are not a complete process-specific leachables risk assessment.
Understand the current framework without overstating it
[REGULATORY REQUIREMENT] For applicable US manufacturing, 21 CFR 211.65 addresses unacceptable interaction between equipment surfaces and process materials or drug products. EU GMP Annex 1 addresses extractables and leachables risk for single-use systems within its sterile-manufacturing scope. These obligations concern suitability and product protection; they do not create one universal laboratory protocol for every polymer.
[COMPENDIAL: APPLICABILITY CHECK] USP provides chapters <665> and <1665> for plastic manufacturing components and systems. The official public USP record checked on 22 September 2026 describes <665> as informational and not compendially applicable unless regulators or enforcement bodies specify otherwise. Therefore, a blanket claim that every single-use component became legally subject to identical testing on a calendar date is not justified by that record.
Use the controlled, current USP text and applicable market requirements to establish the actual implementation. Chapter <1665> provides supporting characterization and qualification context. Manufacturing-system chapters must not be confused with finished-product packaging chapters. Record the edition, scope and rationale used rather than treating a supplier's “USP compliant” statement as a complete assessment.
[INDUSTRY STANDARD / GUIDANCE] BioPhorum's updated extractables protocol, published in April 2020, provides a shared approach to study preparation, extraction and reporting. Scientifically justified modifications can be necessary for particular components. A BioPhorum report and a USP-based report are not automatically interchangeable: compare the actual conditions and coverage. [QRM] ICH Q9(R1) supports proportionate decisions; the following workflow is a [GUIDEGXP RECOMMENDATION].
Build the complete contact inventory
Map components to process steps and identify every material with a plausible migration route. Include films, tubing, connectors, filters, sensor surfaces, seals and adhesive interfaces where relevant. A short branch or small connector should not disappear from the assessment merely because its surface area is small. Component families can be grouped only with a documented representativeness argument.
Capture supplier, manufacturing site where relevant, part number, drawing revision, material grade, sterilization or irradiation condition, shelf-life state and dataset reference. An assembly bill of materials is the starting point; it may not expose all wetted subcomponents or formulation changes. Resolve gaps with the supplier before assigning a low-risk conclusion.
Link the inventory to the actual process route. Buffer-contact components can contribute indirectly when the buffer enters the product stream. Repeated transfers and sequential bags may create cumulative exposure. Record which materials contact the process before and after any claimed removal step, and identify the smallest relevant batch or pool volume.
Describe the use conditions before ranking risk
Record fluid composition, pH, solvent characteristics, salts, surfactants, temperature, wetted area, volume and contact duration. Include preparation, storage, transport, pauses and process interruptions. Process hold time and material contact time can differ: a buffer may already have contacted the bag for an extended period before it enters the defined manufacturing hold.
Consider irradiation or sterilization and subsequent ageing as part of the material state. A gamma dose record describes an exposure history; it does not establish chemical suitability or a sterility assurance claim by itself. Confirm whether the tested state represents the supplied and used component. Do not assume that an unirradiated material report covers an irradiated assembly.
| Assessment input | Why it changes the decision | Evidence expected |
|---|---|---|
| Material and component identity | Similar polymer names can conceal different formulations or manufacturing histories | Traceable grade, component revision and representative dataset |
| Fluid and exposure conditions | Migration depends on chemistry, temperature, duration and surface-to-volume relationship | Process envelope and comparison with study conditions |
| Position in the process | Downstream operations may alter the quantity reaching the final product | Justified fate assessment without assumed clearance |
| Patient administration | Concentration alone does not describe exposure | Dose, route, frequency and treatment duration for toxicological review |
| Analytical capability | An absence of reported peaks may reflect a method limitation | Coverage, sensitivity, recovery and uncertainty assessment |
Review supplier data as evidence
Request the study design, sample identity, pretreatment, extraction conditions, analytical methods and reporting basis. Determine whether results are expressed per component, per area or per extraction volume. Confirm how unknown compounds were quantified and what reference standards or response assumptions were used. A summary table without these details may be impossible to apply reliably.
Check coverage across volatile, semivolatile and less volatile organic compounds and relevant elemental contributors. No single instrument detects every possible migrant. Examine blanks, method sensitivity, matrix effects and the treatment of unidentified signals. A “not detected” statement means only that the substance was not observed under the method's stated capabilities.
Compare study conditions with intended use without assuming that more aggressive always means more representative. Harsh extraction may generate degradation products that would not occur during processing. Less aggressive conditions may miss relevant migration. The bridge should explain which aspects are conservative, which are realistic and which remain uncertain.
Translate chemical results into process exposure
Normalize results onto a consistent basis before summing contributions. A conceptual mass balance can estimate the contribution from each component and then relate the total to the final product quantity. Preserve units and distinguish measured values from extrapolations. Repeated components, concentrated pools and different dose presentations can change the relevant exposure case.
Do not automatically assume that chromatography or UF/DF removes a particular chemical. Clearance depends on the substance and process. Product binding, membrane retention, recirculation and pool selection can make simple dilution assumptions unreliable. Credit a removal factor only when adequate scientific evidence supports it, and document whether the evidence is measured, modelled or conservatively bounded.
Analytical evaluation thresholds help determine which signals require investigation or reporting under a defined study strategy. They are not universal toxicological acceptance limits. A qualified toxicologist should assess relevant hazards, patient route, dose and duration, uncertainty and any substance-specific concerns. Product-quality and cell-culture effects may require separate assessment even when estimated patient exposure is acceptable.
Choose the next action with a decision matrix
| Evidence situation | Reasonable next action | Condition for closure |
|---|---|---|
| Representative data and bounded exposure | Document the scientific bridge and expert review | Residual uncertainty is acceptable for the intended use |
| Correct material but incomplete analytical coverage | Obtain missing data or perform targeted characterization | The missing chemical space is addressed or justified |
| Different sterilization or use conditions | Evaluate a bridging study or relevant simulated use | The effect of the difference is understood |
| Unidentified signal with meaningful exposure potential | Improve identification, quantification and toxicological interpretation | Identity or a justified conservative evaluation supports the decision |
| Unacceptable exposure or product interaction | Change material, process conditions or architecture | Revised conditions are supported by new evidence |
A risk score should guide depth of review, not predetermine that a named score always requires one particular study. Avoid reducing a complex assessment to a traffic-light result while leaving unknowns unresolved. Record the question that each additional experiment will answer and how its result can change the decision.
Design targeted studies around remaining uncertainty
When additional work is necessary, select representative process fluid or an appropriately justified simulant. Define relevant contact conditions and material state. Include controls that separate component-derived signals from fluid impurities, laboratory background and sample-preparation artefacts. Sampling devices and analytical containers can themselves introduce compounds, so their contribution needs consideration.
Decide whether the study addresses a component, an assembly or the complete process train. Assembly testing can capture interactions and the installed configuration, while component data can help identify the source of a signal. Combining the two may be more informative than repeating broad screening without a clear hypothesis.
Predefine reporting, identification confidence, quantification approach and handling of unexpected findings. A study should remain interpretable when results differ from expectations. Retain the rationale for excluded tests and the limits of any extrapolation. Testing cannot repair an incomplete inventory or an undefined process envelope.
Worked example: a buffer bag with apparently reassuring data
Illustrative engineering case. A project qualifies a bag using supplier extractables data generated for the correct film. The bag stores a buffer that later enters a concentrated product pool. The initial assessment considers only the film surface and assumes downstream UF/DF eliminates every small molecule.
Review identifies additional tubing and connectors, a longer material-contact interval than the formal buffer hold, and an unverified clearance assumption. The team updates the contact map and exposure calculation, checks the supplied sterilization state and requests missing component data. Analytical and toxicological specialists identify which contributors need further evaluation.
A targeted study then addresses the remaining process-specific uncertainty. The final conclusion may support use, require tighter operating conditions or justify another material; the outcome depends on evidence. The lesson is that a correct supplier report can coexist with an incomplete user assessment.
Checklist for an approvable assessment
- Define the product, process version, manufacturing stage and intended material-contact envelope.
- Trace every relevant component to its materials, supplier data and installed assembly revision.
- Compare extraction conditions, analytical coverage and tested material state with actual use.
- Assess cumulative contributions and distinguish measured concentrations from modelled exposure.
- Justify any dilution, clearance or removal credit with substance- and process-relevant evidence.
- Document analytical uncertainty, unknown compounds and the scope of toxicological review.
- Record product-quality and process-performance risks separately from patient toxicology.
- Define approval conditions, unresolved limitations, change triggers and ownership of future review.
Common mistakes and lifecycle red flags
Common errors include accepting “same polymer” as equivalence, treating a biological reactivity result as E&L clearance, confusing an analytical threshold with a safety limit and considering only the largest bag. Missing raw-material traceability, unexplained unknown peaks and confidential data that no qualified reviewer can access are substantive gaps.
Supplier changes to resin, additives, film layers, manufacturing site, irradiation or subcomponents can affect the assessment. Lot traceability identifies which material was used; change notification identifies changes that may invalidate the scientific bridge. Define review triggers and manage transition lots. A historical approval remains useful only while its assumptions remain applicable.
Changes on the user side matter equally. A smaller batch, more concentrated pool, longer interruption or different formulation may increase exposure without any supplier change. A new presentation or dosing regimen can change the toxicological evaluation while the manufacturing assembly stays identical. Link the assessment to process and product change control, and retain a concise list of the assumptions whose validity must be rechecked. This makes the original scientific work reusable without turning it into a permanent, unconditional approval.
References and next step
Sources checked 22 September 2026. USP <665> public record and applicability statement; USP <1665> public record; BioPhorum extractables protocol; BioPhorum reporting guidance; 21 CFR 211.65; EU GMP Annex 1; ICH Q9(R1). Proprietary tables and test protocols are not reproduced.
Return to Single-Use & Bioprocess Systems to connect the chemical assessment with material selection, supplier control and qualification.
Related decisions
- Integrity of Single-Use Systems: Bags, Connectors, Filters and Leak Risk Management
- Managing Single-Use System Changes: Supplier Notifications, Material Changes and Lifecycle Control
Explore all decision areas — Single-Use & Bioprocess Systems.
